Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is among several ...
Amgen stock (NASDAQ: AMGN) has seen a solid 9% rise in a week, outperforming the broader S&P500 index, up 1.5%. The recent rise can be attributed to the progress with its weight-loss drug — MariTide ...
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. Also Read: Jim Cramer Says Eli ...
Amgen is scrapping an experimental weight loss pill but moving forward with an injection. Amgen will release initial data from a mid-stage study on its injectable drug later this year, and the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback